Demographics and baseline characteristics
| . | Zanubrutinib (n = 327) . | Ibrutinib (n = 325) . |
|---|---|---|
| Age, median (range), y | 67 (35-90) | 68 (35-89) |
| Male | 213 (65.1) | 232 (71.4) |
| ECOG PS score of ≥1, n (%) | 198 (60.6) | 203 (62.5) |
| Race, n (%) | ||
| White | 261 (79.8) | 265 (81.5) |
| Asian | 47 (14.4) | 44 (13.5) |
| Black or African American | 4 (1.2) | 2 (0.6) |
| Native Hawaiian, Pacific Islander or other | 3 (0.9) | 0 |
| Multiple | 1 (0.3) | 0 |
| Other/not reported/unknown | 11 (3.4) | 14 (4.3) |
| Prior lines of systemic therapy, median (range) | 1 (1-6) | 1 (1-12) |
| >3 prior lines, n (%) | 24 (7.3) | 30 (9.2) |
| del(17p) and/or TP53mut, n (%) | 75 (22.9) | 75 (23.1) |
| del(17p) | 45 (13.8) | 50 (15.4) |
| TP53mut without del(17p) | 30 (9.2) | 25 (7.7) |
| IGHV mutational status, n (%) | ||
| Mutated | 80 (24.5) | 70 (21.5) |
| Unmutated | 240 (73.4) | 241 (74.2) |
| Missing | 7 (2.1) | 14 (4.3) |
| Complex karyotype∗ (≥3 abnormalities) | ||
| Yes | 56 (17.1) | 70 (21.5) |
| No | 153 (46.8) | 130 (40.0) |
| Missing | 118 (36.1) | 125 (38.5) |
| Complex karyotype∗ (≥5 abnormalities) | ||
| Yes | 32 (9.8) | 38 (11.7) |
| No | 177 (54.1) | 162 (49.8) |
| Missing | 118 (36.1) | 125 (38.5) |
| Bulky disease (≥5 cm), n (%) | 145 (44.3) | 149 (45.8) |
| . | Zanubrutinib (n = 327) . | Ibrutinib (n = 325) . |
|---|---|---|
| Age, median (range), y | 67 (35-90) | 68 (35-89) |
| Male | 213 (65.1) | 232 (71.4) |
| ECOG PS score of ≥1, n (%) | 198 (60.6) | 203 (62.5) |
| Race, n (%) | ||
| White | 261 (79.8) | 265 (81.5) |
| Asian | 47 (14.4) | 44 (13.5) |
| Black or African American | 4 (1.2) | 2 (0.6) |
| Native Hawaiian, Pacific Islander or other | 3 (0.9) | 0 |
| Multiple | 1 (0.3) | 0 |
| Other/not reported/unknown | 11 (3.4) | 14 (4.3) |
| Prior lines of systemic therapy, median (range) | 1 (1-6) | 1 (1-12) |
| >3 prior lines, n (%) | 24 (7.3) | 30 (9.2) |
| del(17p) and/or TP53mut, n (%) | 75 (22.9) | 75 (23.1) |
| del(17p) | 45 (13.8) | 50 (15.4) |
| TP53mut without del(17p) | 30 (9.2) | 25 (7.7) |
| IGHV mutational status, n (%) | ||
| Mutated | 80 (24.5) | 70 (21.5) |
| Unmutated | 240 (73.4) | 241 (74.2) |
| Missing | 7 (2.1) | 14 (4.3) |
| Complex karyotype∗ (≥3 abnormalities) | ||
| Yes | 56 (17.1) | 70 (21.5) |
| No | 153 (46.8) | 130 (40.0) |
| Missing | 118 (36.1) | 125 (38.5) |
| Complex karyotype∗ (≥5 abnormalities) | ||
| Yes | 32 (9.8) | 38 (11.7) |
| No | 177 (54.1) | 162 (49.8) |
| Missing | 118 (36.1) | 125 (38.5) |
| Bulky disease (≥5 cm), n (%) | 145 (44.3) | 149 (45.8) |
ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy chain variable.
Centrally assessed.